57 results on '"Porwit, A."'
Search Results
2. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
3. The International Consensus Classification of acute leukemias of ambiguous lineage
4. Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes
5. In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia
6. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia
7. A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients
8. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
9. High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma
10. Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells
11. The WHO classification of MDS does make a difference
12. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
13. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma
14. Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML
15. Chapter 32 - T-Cell Prolymphocytic Leukemia
16. Multicenter Prospective Evaluation of Diagnostic Potential of Flow Cytometric Aberrancies in Myelodysplastic Syndromes
17. Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease
18. C014 Expression of p53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5q)
19. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group
20. Unraveling Actionable Target Mutations in Formalin Fixed Tissue in Mantle Cell Lymphoma
21. Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting
22. Risk Factors for Acute Myeloid Leukemia and Myelodysplastic Syndromes in Patients with Multiple Myeloma: An Updated Analysis
23. Contributors
24. The Impact of Prior Malignancies on Second Malignancies and Survival in MM Patients: A Population-Based Study
25. Outcomes of Mixed Phenotype Leukemia, Not Otherwise Specified (NOS), in Adults: A Single Centre Retrospective Review from 2000 to 2014
26. Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care
27. A Standard, 3-Tube, 10-Color Flow Cytometry Panel for Acute Myeloid Leukemia Diagnosis Can be Used for MRD Detection at Day 30 after Induction, and Is Predictive of Early Relapse
28. Clinical Characteristics and Treatment Outcomes in Patients Diagnosed with Primary Mediastinal Large B-Cell Lymphoma at Princess Margaret Cancer Centre from 1994-2012
29. Diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm By Using 10-Colour Flow Cytometry and Achievement of Remission By Hypercvad Therapy
30. Characterization of diffuse large B-cell lymphomas of the oral cavity
31. Bone Marrow Fibrosis In Patients With Multiple Myeloma: A New Prognostic Factor For Survival?
32. Development of Hodgkin lymphoma in homozygotic triplets with constitutional deletion in MKL1
33. P-098 p53 protein expression predicts outcome and cytogenetic response in patients with low-/INT-1-risk myelodysplastic syndromes treated with lenalidomide
34. Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,
35. 135 Lower bone marrow myeloid and plasmacytoid dendritic cell counts in high-risk than in low-risk MDS patients and controls
36. 137 Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group
37. Response: Factors considered in the 2008 WHO classification of myeloid neoplasms and acute leukemias
38. Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression
39. Arachidonic Acid Metabolism-Related Molecules as Candidate Markers in Subclassification of Lymphoma
40. European Leukemianet (ELN) Project Diagnostic Platform (WP10): Final Results of the First Study of the European Morphology Consensus Panel.
41. Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy
42. Novel Findings Support a Patophysiological Role of the Arachidonic Cascade in Hodgkin Lymphoma.
43. Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.
44. P136 Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need
45. Leukotrienes Stimulate the Release of Cytokines and Proliferation of Hodgkin Reed-Sternberg Cells.
46. Studies on the distribution of abnormal cells in cytological smears: VII. Cervical brush versus plastic and wooden spatulas
47. ANALYSIS OF STRUCTURAL DEPENDENCES IN CENTRAL PLAN CONSTRUCTION
48. CHAPTER 28 - The chronic lymphoid leukemias
49. CHAPTER 19 - Acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemias
50. CHAPTER 20 - Myelodysplastic syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.